findmyKOL
Clinical trialNCT04889716RecruitingPhase 2Interventional

CAR-T Followed by Bispecific Antibodies

SponsorAbramson Cancer Center at Penn MedicineEnrollment23DLBCL - Diffuse Large B Cell LymphomaLarge B-cell Lymphoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The research study is being conducted to test the safety and effectiveness of the experimental drug mosunetuzumab (Cohort 1) or obinutuzumab and glofitamab (Cohort 2) when given after CAR (genetically modified) T cells. The study is for patients who have already received a CAR T-cell infusion. Some patients who join the study will receive mosunetuzumab, other patients later in the study may receive a different experimental drug (glofitamab, in combination with obinutuzumab).
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Nebraska Medical Center

    Omaha, Nebraska, United States

    Christopher D'Angelo, MDJulie Vose, MDRobert Gregory Bociek, MDSnegha Ananth, MD
    Recruiting
  • Abramson Cancer Center of the University of Pennsylvania

    Philadelphia, Pennsylvania, United States

    Elise A. Chong, MDJakub Svoboda, MDStephen J. Schuster, MD →
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Glofitamab →Mosunetuzumab →Obinutuzumab →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
5 Nov 2021
Primary completion
31 Dec 2027
Completion
31 Dec 2028
Last update posted
26 May 2026
Registered enrollment
23
Registry id
NCT04889716
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.